Posts

Revolution Medicines Secures $2B Funding from Royalty Pharma for RAS Cancer Drugs as Biotech Sector Heats Up

on
Revolution Medicines announced a $2 billion flexible funding agreement with Royalty Pharma on June 24, 2025, including up to $1.25B in synthetic royalties on daraxonrasib sales and $750M in debt. 1 2 The deal supports independent global development and commercialization of RAS(ON) inhibitors like daraxonrasib for NSCLC and PDAC, without needing a Big Pharma partner. 1 2 Revolution received the first $250M tranche immediately, with more tied to milestones like Phase 3 PDAC study success; royalties start at 4.55% on first $2B sales. 1 2 Company ended March with $2.1B cash, now extending runway significantly and pursuing global commercialization strategy. 1 2 Query mentions XBI reaching pandemic highs, signaling strong biotech market sentiment amid this financing news, though specifics on XBI not detailed in sources. 6 Sources: 1. https://www.fiercebiotech.com/biotech/royalty-signs-2b-bankroll-revolutions-ras-cancer-drugs-road-approval 2. https://www.biospace.com/press-relea...

Bristol Myers Squibb and Bain Capital Launch New Autoimmune Disease Biotech Company

on

Biogen's $5.6B Apellis Acquisition: Key Biotech Deals Including Telix's $600M Raise and Obsidian's IPO Plans

on

Spotlight On: Tackling Core Challenges in Drug R&D with AI

on

Johnson & Johnson Reports Strong Q1 Results and Raises 2026 Guidance

on

FDA Requests Additional Safety Data from Eli Lilly on Foundayo for Liver and Heart Risks

on

Astellas Pharma to Close Seattle Universal Cells Office with 50 Employee Layoffs

on

MinervaX Strengthens Executive Leadership Team with Two Strategic Appointments as it Advances its Maternal GBS Vaccine Towards Pivotal Trial Initiation

on

Obsidian Therapeutics Goes Public Through Galera Reverse Merger with $350M PIPE Financing

on

Novo Nordisk Partners with OpenAI to Accelerate Drug Development

on

Rancho BioSciences Appoints Amar Thyagarajan as Chief Commercial Officer

on

Harbinger Health Raises $100M for Multi-Cancer Blood Detection Platform

on

Travere Therapeutics Receives FDA Approval for Filspari as First FSGS Treatment

on